文献速递心脑血管急症重症综合管理与镇静镇痛

利伐沙班用于不明原因栓塞性卒中后的卒中预防

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
PubMed 文献 · N Engl J Med · 2018-05-16
一句话结论在不明原因栓塞性卒中后,利伐沙班每日15 mg在预防复发性卒中方面不优于阿司匹林每日100 mg,且大出血风险更高。

NAVIGATE ESUS试验纳入7213例近期缺血性卒中患者,该卒中推测源于脑栓塞但无动脉狭窄、腔隙灶或已识别的心源性栓塞源,随机分配至利伐沙班每日15 mg组(3609例)或阿司匹林每日100 mg组(3604例)。主要疗效终点(首次复发性缺血性或出血性卒中或系统性栓塞)在利伐沙班组172例(年化率5.1%)、阿司匹林组160例(年化率4.8%)发生(HR 1.07;95%CI 0.87-1.33;P=0.52)。大出血在利伐沙班组62例(年化率1.8%)、阿司匹林组23例(年化率0.7%)发生(HR 2.72;95%CI 1.68-4.39;P<0.001)。试验因利伐沙班在卒中风险方面缺乏获益及出血风险而提前终止。

要点

  • 在不明原因栓塞性卒中患者中,利伐沙班每日15 mg组主要疗效终点年化率5.1%,阿司匹林每日100 mg组4.8%(HR 1.07;95%CI 0.87-1.33;P=0.52),利伐沙班不优于阿司匹林。
  • 利伐沙班组大出血年化率1.8%,阿司匹林组0.7%(HR 2.72;95%CI 1.68-4.39;P<0.001),利伐沙班出血风险更高。
  • 试验因利伐沙班在卒中风险方面缺乏获益及出血风险而提前终止,患者中位随访11个月。
  • 复发性缺血性卒中在利伐沙班组158例(年化率4.7%)、阿司匹林组156例(年化率4.7%)发生。
  • 该研究针对的是推测源于脑栓塞但无动脉狭窄、腔隙灶或已识别心源性栓塞源的近期缺血性卒中患者。

适用人群与场景

  • 近期缺血性卒中患者,推测源于脑栓塞但无动脉狭窄、腔隙灶或已识别的心源性栓塞源。

诊断标准与关键阈值

  • 不明原因栓塞性卒中:推测源于脑栓塞的缺血性卒中,无动脉狭窄、腔隙灶或已识别的心源性栓塞源。

处置流程与药物剂量

  • 利伐沙班每日剂量15 mg口服用于预防复发性卒中。
  • 阿司匹林每日剂量100 mg口服用于预防复发性卒中。

研究设计与关键结果

  • NAVIGATE ESUS为随机对照试验,纳入7213例患者,来自459个中心,随机分配至利伐沙班每日15 mg组(3609例)或阿司匹林每日100 mg组(3604例),中位随访11个月,因利伐沙班在卒中风险方面缺乏获益及出血风险而提前终止。
  • 主要疗效终点(首次复发性缺血性或出血性卒中或系统性栓塞)在利伐沙班组172例(年化率5.1%)、阿司匹林组160例(年化率4.8%)发生(HR 1.07;95%CI 0.87-1.33;P=0.52)。
  • 复发性缺血性卒中在利伐沙班组158例(年化率4.7%)、阿司匹林组156例(年化率4.7%)发生。
  • 大出血在利伐沙班组62例(年化率1.8%)、阿司匹林组23例(年化率0.7%)发生(HR 2.72;95%CI 1.68-4.39;P<0.001)。

证据类型、等级与局限

  • 证据类型:随机对照试验(NAVIGATE ESUS,ClinicalTrials.gov NCT02313909),由Bayer和Janssen Research and Development资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于推测源于脑栓塞但无动脉狭窄、腔隙灶或已识别心源性栓塞源的近期缺血性卒中患者,利伐沙班每日15 mg在预防复发性卒中方面不优于阿司匹林每日100 mg,且大出血风险更高(年化率1.8% vs 0.7%,HR 2.72)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin.

METHODS: We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The primary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic embolism in a time-to-event analysis; the primary safety outcome was the rate of major bleeding.

RESULTS: A total of 7213 participants were enrolled at 459 sites; 3609 patients were randomly assigned to receive rivaroxaban and 3604 to receive aspirin. Patients had been followed for a median of 11 months when the trial was terminated early because of a lack of benefit with regard to stroke risk and because of bleeding associated with rivaroxaban. The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 0.87 to 1.33; P=0.52). Recurrent ischemic stroke occurred in 158 patients in the rivaroxaban group (annualized rate, 4.7%) and in 156 in the aspirin group (annualized rate, 4.7%). Major bleeding occurred in 62 patients in the rivaroxaban group (annualized rate, 1.8%) and in 23 in the aspirin group (annualized rate, 0.7%) (hazard ratio, 2.72; 95% CI, 1.68 to 4.39; P<0.001).

CONCLUSIONS: Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Development; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018. PMID: 29766772. doi:10.1056/NEJMoa1802686

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。